Promethera’s mission is to apply its proprietary liver cell-based technology to meet the needs of patients with acute and chronic liver diseases.
French version available soon
Promethera is pioneering the development of novel cell-based therapies for the treatment of a broad variety of liver diseases. The Company’s platform has the potential to deliver novel therapeutic options for inherited disorders including hemophilia as well as acquired chronic and acute liver diseases such as Acute-on-Chronic-Liver Failure (ACLF), fibrosis and Non-Alcoholic Steatohepatits (NASH).
Promethera’s lead clinical program is derived from a patented allogenic liver cell platform called HepaStem. Currently in an open-label Phase 2 clinical trial to treat patients with Acute-on-Chronic-Liver Failure (ACLF), the program is expected to enter clinical development in Non-Alcoholic Steatohepatits (NASH) in the second half of 2017.
Promethera Biosciences is headquartered in Mont-Saint-Guibert in the Walloon region of Belgium, which is internationally known for excellence in cell therapy research. Located at the Belgian site are GMP certified manufacturing facilities. The Company’s US subsidiary, Promethera Biosciences LLC, has facilities in Durham, North Carolina. These include commercial operations; GMP certified manufacturing facilities and the organ procurement relations department.
Get a brief overview of Promethera's activities and view our latest corporate presentation.
Since inception, Promethera Biosciences has raised EUR 48.6 million in equity from a broad range of leading European and Asian investors.
Promethera has outstanding capabilities and expertise in liver biology and cell-based medicine. These activities currently include the use of HepaStem in hemophilia and the Heparesc product line. more